PPARG and metabolic dysfunction-associated steatotic liver disease: The increased expression of Pparγ2 and its target genes in the livers of obese mouse models and humans with NAFLD (8, 20, 46, 47), i.e. under conditions of insulin resistance, might appear contradictory.